Patent: 7,320,961
✉ Email this page to a colleague
Summary for Patent: 7,320,961
| Title: | Method for treating a disease, disorder or adverse effect caused by an elevated serum concentration of an UGT1A1 substrate |
| Abstract: | The present invention is directed to a method for inducing UGT1A1 isoform expression for treatment of a disease, disorder or adverse effect caused by an elevated serum concentration of an UGT1A1 substrate comprising the step of administering to a subject an effective amount of ritonavir. In particular, the present invention is directed to a method of treating unconjugated hyperbilirubinemia by UGT1A1 induction comprising the step of administering to a subject an effective amount of ritonavir. |
| Inventor(s): | Kempf; Dale J. (Libertyville, IL), Bertz; Richard J. (Kenosha, WI), Waring; Jeffrey F. (Franklin, WI) |
| Assignee: | Abbott Laboratories (Abbott Park, IL) |
| Application Number: | 10/802,829 |
| Patent Claims: | see list of patent claims |
Details for Patent 7,320,961
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Clinigen, Inc. | PROLEUKIN | aldesleukin | For Injection | 103293 | 05/05/1992 | ⤷ Try a Trial | 2023-03-24 |
| Partner Therapeutics, Inc. | LEUKINE | sargramostim | For Injection | 103362 | 03/05/1991 | ⤷ Try a Trial | 2023-03-24 |
| Partner Therapeutics, Inc. | LEUKINE | sargramostim | Injection | 103362 | 03/05/1991 | ⤷ Try a Trial | 2023-03-24 |
| Bayer Healthcare Pharmaceuticals Inc. | BETASERON | interferon beta-1b | For Injection | 103471 | 07/23/1993 | ⤷ Try a Trial | 2023-03-24 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
